Particle physics needs a new collider to supersede the Large Hadron Collider. Muons, not electrons or protons, might hold the key.
Horizon Aeronautics is prototyping an eVTOL hovercycle concept that uses a complex and interesting split-swashplate “Blainjett” variable pitch rotor system that only exposes half of each fan. Very odd, but Horizon says it’s highly efficient.
To understand how this Blainjett propulsion system works – and before anyone asks, no, these guys are no relation to me – you first need to understand how the swashplate and cyclic controls work to distribute thrust as a helicopter’s top rotor spins. Each blade can vary its pitch independently, with the height of the swashplate determining the pitch. With the swashplate sitting flat, pushing the whole thing up and down will change the pitch of all the blades at once.
But with the cyclic control, helicopter pilots are able to tilt the swashplate. Pushing the stick forward, for example, tilts it such that the blades gradually tilt as they spin around, getting flatter as they pass the front of the aircraft, then pitching up to develop more lift as they go around the back. The result is an asymmetry in lift, with more at the back of the disc, and the aircraft pitches forward and accelerates in that direction. The cyclic control can do this in any direction; it’s part of what makes helicopters such dynamic aircraft.
Roughly 13.8 billion years ago, our Universe was born in a massive explosion that gave rise to the first subatomic particles and the laws of physics as we know them.
About 370,000 years later, hydrogen had formed, the building block of stars, which fuse hydrogen and helium in their interiors to create all the heavier elements. While hydrogen remains the most pervasive element in the Universe, it can be difficult to detect individual clouds of hydrogen gas in the interstellar medium (ISM).
Continue reading “Astronomers Discover One of The Biggest Structures Ever Seen in The Milky Way” »
A COVID testing site says it has detected what is believed to be the first ‘flurona’ co-infection, a combination of influenza and coronavirus, in Los Angeles County.
Peter Hotez and Maria Elena Bottazzi used an oldie-but-goodie technology to devise a vaccine that’s easy to make — and relatively cheap. India has already ordered 300 million doses.
During 2021, thousands of archaeologists worked tirelessly to continue to excavate, explore, publish, and keep the field alive across the globe.
Support Hyperallergic’s independent arts journalism. Become a Member ».
Google is bringing Fast Pair to Windows and TVs and more. It’s also planning Wear OS watch unlocks for phones.
Google laid out its plans for a number of new features coming to its ecosystem of devices and operating systems this year, a lot of which is focused on connecting them all or making setup easier. Whether you have an Android phone and an Android TV or a Chrome OS devices and a Wear OS watch, there is a good chance they will start to talk to each other.
Quicker setup of all devices
Continue reading “Google’s 2022 Plans are to Connect It All, Including Android…” »
The incredible image was taken by hand using a digital camera onboard the International Space Station.
NASA’s Earth Observatory has released a photo of a crescent moon above an orbital sunset taken by an astronaut on the International Space Station.
Exactly what existed before the birth of our own Universe remains a mystery, but that is not stopping some physicists from trying to figure it out.
Artificial intelligence drug design company Iktos, and South Korean clinical research biotech Astrogen announced today a collaboration with the goal of discovering small-molecule pre-clinical drug candidates for a specific, undisclosed, marker of Parkinson’s disease (PD).
Under the terms of the agreement, whose value was not disclosed, Iktos will apply its generative learning algorithms which seek to identify new molecular structures with the potential address the target in PD. Astrogen, which has a focus of the development of therapeutics for “intractable neurological diseases,” will provide in-vitro and in-vivo screening of lead compounds and pre-clinical compounds. While both companies will contribute to the identification of new small-molecule candidates, Astrgoen will lead the drug development process from the pre-clinical stages.
“Our objective is to expedite drug discovery and achieve time and cost efficiencies for our global collaborators by using Iktos’s proprietary AI platform and know-how,” noted Yann Gaston-Mathé, president and CEO of Paris-based Iktos in a press release. “We are confident that together we will be able to identify promising novel chemical matter for the treatment of intractable neurological diseases. Our strategy has always been to tackle challenging problems alongside our collaborators where we can demonstrate value generation for new and on-going drug discovery projects.”
